Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.62 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.62 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.62 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.62 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.62 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.62 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.60 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3590191 | 0.85 | SMN1; SMN2 (0.73) | SMN1; SMN2HIF1AL3MBTL1KMT2AMEN1 | |
| SCHEMBL3030085 | 0.85 | HDAC8 (0.61) | SMN1; SMN2HDAC1HDAC6HDAC2HDAC8 | |
| SCHEMBL2912570 | 0.84 | SMN1; SMN2 (0.82) | SMN1; SMN2HIF1AL3MBTL1KMT2AMEN1 | |
| SCHEMBL13947384 | 0.82 | SMN1; SMN2 (0.73) | SMN1; SMN2L3MBTL1KMT2AMEN1NPC1 | |
| SCHEMBL14531874 | 0.82 | SMN1; SMN2 (0.73) | SMN1; SMN2HIF1AL3MBTL1KMT2AMEN1 | |
| SCHEMBL95008 | 0.82 | SMN1; SMN2 (0.73) | SMN1; SMN2HIF1AL3MBTL1KMT2AMEN1 | |
| SCHEMBL28649262 | 0.79 | SMN1; SMN2 (0.69) | SMN1; SMN2HIF1AL3MBTL1KMT2AMEN1 | |
| SCHEMBL1568246 | 0.79 | SMN1; SMN2 (0.68) | SMN1; SMN2SCN2ASCN10AL3MBTL1KMT2A | |
| SCHEMBL3025457 | 0.78 | HDAC6 (0.91) | HDAC1HDAC6HDAC2HDAC8HDAC3 | |
| SCHEMBL8160653 | 0.78 | HIF1A (1.00) | SMN1; SMN2HIF1AL3MBTL1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | claimed |
| EP-2205070-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009045385-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | MERCK & CO., INC. (US) | 2009-04-09 | — | — | WO | claimed |
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | KATTAR SOLOMON | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216796-A1 | N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS | BRDT, AADAC, ACIN1 | SMN1; SMN2 921/4885HIF1A 793/4885HDAC1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.